Mad Money 11/11/26 | Audio Only

Mad Money 11/11/26 | Audio Only

Analysé Voir sur YouTube Demandé Le
Rendement de la vidéo
-5,36%
Appels
4
Achat / Vente
4 0
Publié

Recommandations

L'entrée est le cours de clôture de l'actif à la date de publication. Le cours actuel est la dernière clôture enregistrée.

  1. 01 BABA NYSE ACHETER -20,13%
    Entrée $101,52 11 nov 2026
    Actuel $81,08 20 nov 2026
    Résultat −$20,44
    vs. indice −10,9% SPY −9,2% sur la même période
    Contexte de la transcription source
    …'s time for the light. You're playing the sound and then the lightning round is over. Are you ready? Ski daddy. Time for the light round claims. Let's start with Ronald in Florida. Ronald >> Jim Ronald from Wellington, Florida. Alibaba. >> I think Alibaba is the only Chinese stock that I would possibly buy. It's not my favorite right now because the consumer is so weak in China, but it is the only one that I would buy. Let's go because it's got American Financials. Let's go to Roy in New Jersey. Roy, you're happy. >> Hey, Jim. Boy, it's a great pleasure for me to be talking to you. Uh, you're very kind, boy. What's going on? >> The ticker I have is TGB, …

    I think Alibaba is the only Chinese stock that I would possibly buy. It's not my favorite right now because the consumer is so weak in China, but it is the only one that I would buy.

    Contexte extrait par IA Let's start with Ronald in Florida. Ronald >> Jim Ronald from Wellington, Florida. Alibaba. >> I think Alibaba is the only Chinese stock that I would possibly buy. It's not my favorite right now because the consumer is so weak in China, but it is the only one that I would buy. Let's go because it's got American Financials.

  2. 02 OBK NYSE ACHETER +0,00%
    Entrée $54,24 11 nov 2026
    Actuel $54,24 10 nov 2026
    Résultat +$0,00
    vs. indice +9,2% SPY −9,2% sur la même période
    Contexte de la transcription source
    …I want to get your thoughts on one of my favorites, uh, Origin Bank Card, symbol OBK. >> You know, I've got to tell I've actually made a lot of money buying Louisiana banks over the multiple years because there's a lot of consolidation and this is an inexpensive bank stock. Not that good a yield, but I like it. I think you got a good one and I and I actually would encourage you to buy it. Let's go to John in New Jersey. John, >> oh yeah, Jim. >> Oh yeah. >> Um, it's John from Egg Harbor Township. What's your opinion on Palunteer? >> My dad did a lot of business in Egg Harbor. There were like free retail stores that he sold …

    this is an inexpensive bank stock. Not that good a yield, but I like it. I think you got a good one and I and I actually would encourage you to buy it.

    Contexte extrait par IA Let's go to Bill in Texas. Billy, Jim, >> proud proud club member here and a long time listener. Uh you're still the best. >> A thank you, man. Thank you. Thank you very much. Thank you. How can I help? I want to get your thoughts on one of my favorites, uh, Origin Bank Card, symbol OBK. >> You know, I've got to tell I've actually made a lot of money buying Louisiana banks over the multiple years because there's a lot of consolidation and this is an inexpensive bank stock. Not that good a yield, but I like it. I think you got a good one and I and I actually would encourage you to buy it. Let's go to John in New Jersey. John,

  3. 03 DRI NYSE ACHETER -1,40%
    Entrée $228,94 11 nov 2026
    Actuel $225,74 20 nov 2026
    Résultat −$3,20
    vs. indice +7,8% SPY −9,2% sur la même période
    Contexte de la transcription source
    …s an awful lot of room to run. Chris in Louisiana. Chris. >> Hey, Jim. >> All right. What's happening? >> Can Can we talk stakes? >> Yeah, why not? >> Dart restaurants. Darden restaurants. Jim, should I saddle up or should I saddle out? >> I think that look, I think is absolutely terrific. They offer great value at Olive Garden. I think you should continue to buy the stock. It's even though it's on a spike, I think it does go higher. All right. There's much more mad money ahead, including my exclusive with Tea Pharmaceutical. Then this Veterans Day, I'm shining a light on one fantastic executive whose military service influenced his career and the company itself. And o…

    I think that look, I think is absolutely terrific. They offer great value at Olive Garden. I think you should continue to buy the stock. It's even though it's on a spike, I think it does go higher.

    Contexte extrait par IA Chris in Louisiana. Chris. >> Hey, Jim. >> All right. What's happening? >> Can Can we talk stakes? >> Yeah, why not? >> Dart restaurants. Darden restaurants. Jim, should I saddle up or should I saddle out? >> I think that look, I think is absolutely terrific. They offer great value at Olive Garden. I think you should continue to buy the stock. It's even though it's on a spike, I think it does go higher. All right. There's much more mad money ahead, including my exclusive with Tea Pharmaceutical.

  4. 04 ET NYSE ACHETER +0,10%
    Entrée $19,43 11 nov 2026
    Actuel $19,45 11 nov 2026
    Résultat +$0,02
    vs. indice +9,3% SPY −9,2% sur la même période
    Contexte de la transcription source
    …We both own shares in energy transfer. I bought the shares for potential growth and its dividends. I got two questions for my shares. Should I buy more, hold or sell? For my grandson, should I buy more, hold or sell, and reinvest? >> Okay. For you, I want you to buy more. I think it's sort of for your grandson, it's not risky enough, believe it or not. What you have to do is you have to buy something that has more uh growth to it and and but nothing crazy. I mean, I'm talking about a J&J. I'm talking about …

    For you, I want you to buy more.

    Contexte extrait par IA Hank in Indiana. Hank. >> Yes. Hello, Mr. Kramer. >> Hey, Hank. What's up? >> Thanks for taking my call. I'll get right to the point. >> All right. >> I'm in my mid70s. My grandson's 10 years old. We both own shares in energy transfer. I bought the shares for potential growth and its dividends. I got two questions for my shares. Should I buy more, hold or sell? For my grandson, should I buy more, hold or sell, and reinvest? >> Okay. For you, I want you to buy more. I think it's sort of for your grandson, it's not risky enough, believe it or not. What you have to do is you have to buy something that has more uh growth to it and and but nothing crazy. I mean, I'm talking about a J&J. I'm talking about a Proctor and Gamble. I would do that because you do not need to worry. You got your He's got his whole life ahead of him. I say don't do that. Buy something more aggressive. Let's go to Spars in California. Spars. Red, white, and blue. 250 years of American exceptionalism. Veterans Day. Booya. Ski.

Transcription Complète
My mission is simple, to make you money. I'm here to level the playing field for all investors. There's always a bull market somewhere, and I promise to help you find it. Mad Money starts now. Hey, I'm Kramer. Welcome to Mad Money. Welcome to Cray America. Other people, my friends, I'm just trying to save you some money. My job is not just to entertain, but to tell it as it is. So call me at 1800743 CBC or tweet me at Jim Kramer. Sometimes you need a reality check even if you are a huge believer in something. The events at Nvidia, including the likelihood tonight that CEO Jensen Wong would be out at the company, perhaps as early as tonight because of another sex scandal, this time with a high-ranking employee, as well as a negative impact to the data center story stemming from the outcome of the big blue wave, have shaken me, made me gunshy about a host of tech stocks, many of which have cost investors fortunes. But on a day when the semiconductor stocks shown on a day while the rest of the averages Dow climbing 255 points SB jumping 1.3% NASDAQ soaring 1.6%. We got some concrete evidence that you write off this group at your own peril. We want to stay diversified but giving up on the data center stocks entirely. They cause you to miss a good amount of upside. Now my chapel trust which you can join by uh going to the CBC investing club. We've taken some data center and related stocks off the table. Unfortunately not Nvidia because our composure and our prudence dictates that to have so much data center is still too dicey. I'm not changing that position even after some of these stocks are now above where we sold them. Still, we've left plenty of exposure to the group, which includes semis software networking builders turbines, and cooling equipment because we think the AI theme has much more room to run. But to keep what we call an overweight position in the group these days, you need nerves of tungsten and the confidence of a highwire walker. That's why I thought an interview we did this very morning on Squawk in the street with Michael Intrader, the CEO of the leading Neocloud Cororeweave, was so refreshing and reassuring, particularly versus the hideous news that seems to be coming out of Nvidia with the big blue wave, a couple of high-profile hedge fund blowups, the weakness in the merger market with Marvel Tech and Lummen, and the heartbreak of an Nvidia possibly without Jensen Wong. All things considered, I would rather be in Colgate or Johnson Johnson. The greatest investing story ever told became almost overnight a blight on our country with its chief spokesperson caught up in some toddry spy scandal that made Theronos look like child's play. With another revelation tonight, Jensen ger unlike print television interviews tend to live for a few minutes and then die. Most of the time they are immediately cremated. But I don't want this one to end up in an earn on top of your TV set. So, let me tell you what intrader said, which might turn you into less of a skeptic as we head into what most likely will be the biggest IPO of all time. Anthropic. While the bankers pitched a 1.3 to 1.4 trillion valuation yesterday morning, by last night, there were already rumors it could be increased to $ 1.5 trillion, meaning by this time next week, we'll be talking maybe 1.6 1.7 trillion. Seems seems totally reasonable. We were a little prosecutorial during the interview this morning with intrader because his company Cory was heavily in debt in large part because intrader is such a huge believer in the long-term value of the data center itself. He's a gigantic buyer of Nvidia chips which cost fortunes. So he has to borrow fortunes to do so. Fortunes that look to be far in excess of his company's means at least right now. But the first thing in trader did was disabuse us the value of what he's buying. Explaining that demand for compute that's the end product of what he buys for it exceeds the supply of it. They are he said 10 times over subscribe for 2027 and he added demand for 2028 is also multiples of what he can provide. What a bullish story. That insatiable demand has allowed him to raise price for services pretty consistently which expands his gross margins. a terrific barometer of future profits, even if they aren't there today. He was borrowing money in the open market by issuing bonds, but those those bonds have been clobbered to the point where they now offer a 15% yield. Now, that's usually a sign of pinning failure. So, he's adapted instead taking down a different kind of debt that has customer prepayments to fund his GPU buying to Nvidia. His debt problem is no longer front and center. When I pressed him, I asked him why he doesn't just go into the open market and buy those bonds that are trading. so poorly, he admitted that he's that he's tempted because he thinks they're very cheap. But ultimately, he still believes that he can make an even better return building and running data centers. In any case, I think you can take the red flag off the table about that issue. But how about the big blue wave and the political blowback that now seems to doom the data center in our country. He said it's not going to slow down the building one bit and that if we don't build them here, then we'll simply go overseas when the rules aren't as strict. There is a massive ground swell of demand around the world of computing, he told us. Do you know he wrote an open letter recently to the new governor of Texas, governor elect, who seems lukewarm on data centers, explaining the core weave is what I call a white hat. He says he expects no trouble putting up data centers there. I felt very good after that because there hasn't been much in the way of positive sentiment ever since voters rejected data centers in 40 of 41 ballot initiatives. Perhaps the most exciting part of the interview, although it was done before a lot more revelations, was when Intrader revealed that Nvidia chips he installed four years ago will soon be earning much more than when he bought them. The technology, he said, is coming off contract next year. Has it has now been recontracted at a 20 to 50% premium to their initial prices. That's right. Starting next year, he'll begin earning more Nvidia chips that he bought four years ago than he has been for any of the past four years. They have increased in value. Now, keep in mind when he initially bought these ships, he borrowed on terms that matched his 5-year customer contracts, but beginning next year, Cororeweave will own them free and clear. So, all the revenue that it gets for renting them out is pure profit. Now, that's incredible. When this company started, there were plenty of people who thought these Nvidia chips would be worthless after one 5-year contract. and trader is making a huge bet on this technology and it's looking like a good one despite what Jensen Wong is said to be up to which led somewhat obviously to Jensen uh who is now the most pillared person in business. I wanted to know if Jensen were out what would he think of the company? a pretty preient question. His response, look, Nvidia is an extraordinary company, right? It is not one person. It is an extraordinary company. There are thousands of people over there that uh interface with thousands of people at my company every day. They they integrate on the technology. They integrate on the uh physical infrastructure. They integrate on the networking. We we have a close relationship with them up and down the companies and they are uh uh a great partner. They have been a great partner for us for years. They will continue to be a great partner for us. Look, I think the chips are obviously going to be worthwhile, but as an Nvidia shareholder and that's my trust that owns it, that's definitely not going to be enough. Look, a chestless Nvidia is an Nvidia many will not want to own. I've always said own it, don't trade it. Well, I didn't think this would happen. I don't know anyone who did. It's very sobering. But Cororeweave's quarter in this interview with intrader are why the NASDAQ went higher today. Yes, it was shockingly positive. Corweave stock itself gain be at 25% today. Had he been less sanguin and less boisterous, maybe we would not have paid as much attention as we did. But that and the fact that Oracle, a builder of data centers, saw it stock war after David Faber's interview with the CFO, Hillary Maxon, who talked about that company's success in building data centers embolden me. Clearly, others felt the same way based on the action today. Would I still buy some more of these tech stocks right here if Jensen's out? The only things uh that would inhead of us that could stop us would be a bad quarter for Nvidia. I don't think we'll get that. But obviously Jensen not on the quarter is going to shock people. What can you do? And then the anthropic deal which should trade next Thursday. Like I said in last night's installment of know your IPO series, anthropics go sounds super. But stay tuned for the next leg tonight when we discuss profitability. Here's the bottom line. Today the markets seem to feel much better about tech and the AI data center. If your port portfolio benefited from that, you can thank Michael Intrader, uh, as news reports certainly say, well, then tomorrow it's going to be a different story. And I am, yes, heartsick about it. I thought I knew, Jensen, maybe we leave it at that. Speak to Gary in Alabama. Hey Jim, first of all, I want to let you know I was one of your original investment club members and I really appreciate what you and Jeff do for guys like me who don't have time to to do the homework and you do that for me and I've made a lot of money with you. >> Thank you, Gary. That's really what we're trying to offer institutional research for individuals but in a way that's far more interesting and understanding. How can I help you? >> Absolutely. Well, I bought Meta just ahead of earnings, which turned out to be a mistake, and I made a lot of money off that stock over the years, but I I was trying to get back in it, and uh and that didn't play out well, but I want to know if it's a good if now is a good time to to jump back in into that. >> I I like Medicare be out. Uh probably maybe out is what I'm talking and and that could because such a big stock and you get a chance to buy it cheaper, I would go do it. Let's go to Gus in Georgia, please. Gus, >> Jim, this is Gus in Atlanta. >> Hey, Gus. >> Jim, I'm a I'm a proud Investing Club member and I've had the honor of meeting you and Jensen Wong last fall at your investment club meeting at the New York Stock Exchange. What an incredible experience that was. >> Thank you. Thank you. >> And Jim, I start and end every day watching you on CNBC. I love your book, How to Make Money in Any Market. Thank you. >> Truly changed my life, my family and I. Thank you. >> Thank you. I really appreciate that. Thank you very much. >> Oh, hey. Thank you. So, my question is about Jersey Mike with former Wingstop CEO Charlie Morrison at the helm. Aggressive US expansion and international growth beginning in London last week. I love its potential. Jim, the stock's been down but is starting to rebound. What's your take? >> Yeah, it's starting I I think it's an inexpensive stock. relative to what I think Charlie's going to be able to do. I was not happy, you know, right out of the shoot. The first numbers were not what I wanted, but I think they can get better cuz Charlie's that good. All right. Uh, typically I just talk about what's going to be on my money tonight. Uh, we're reading the chances out. Okay. Now, I got to tell you, I have to scramble. You have to scramble. I feel terrible that I didn't cut that I didn't cut this one big game. It happens. It actually No, it doesn't happen. This is incredible. And uh sometimes incredible things happen and it's just too bad. We are going to talk about the upcoming anthropic IPO focusing one of the more convoluted aspects profitability. And don't miss my analysis. Then are the restaurant stocks poised for a comeback amid a tough tape for tech? We go off the charts to find out. He Far Pharmaceuticals got some really good stuff. We're going to sit down with the CEO. And again, look, am I broken up? I had nothing in my life broken up and not this one. This one's just disgusting. Stay. Don't miss a second of MadMoney. Follow Jim Kramer on X. Have a question? Tweet Kramer #madmentions. Send Jim an email to madmoney@cnbc.com or give us a call at 1800743cnbc. Miss something? Head to madmoney.cnbc.com. cnbc.com. This week, we're running a know your IPO series on Anthropic ahead of the company's IPO next week. I want you to be fully prepared for what looks like the largest IPO in history. So, I'm covering the story from all angles. Last night I talked about the incredible growth that Anthropic has shown which is the main reason why its valuation has soared and there's so much interest in this deal. But tonight I'm going to tackle a a more difficult subject. Tonight I'm going to tackle the company's profitability. I want to start with the most positive points. Most notably on an adjusted operating income basis. Anthropic became profitable for the first time in the second quarter of 2026. And it's adjusted operating margin. Adjusted operating income divided by revenue was positive again in the third quarter even as it fell a bit from the second quarter. Looking at the first nine months of 2026 as a whole, Anthropic is profitable on both an adjusted operating income and adjusted net income basis. To be clear, Anthropic achieving profitability even on this adjusted operating income basis is no small matter. Last night, the Wall Street Journal reported some third quarter results for Anthropic's chief rival, OpenAI. And the key takeaways were that OpenAI's revenue growth accelerated in the third quarter. Oh, that's positive. But it is still deeply unprofitable with an adjusted operating margin of negative 109%. Truly, Anthropic is doing much better on the profitability front than OpenAI, and that's a big reason why it is going to be the first of the two leading AI labs to make it to market. Now in a more stringent generally accepted accounting principles or you may see that as gap basis Anthropic is not yet profitable but it's close at least for the operating income line. So now I want to dig into the adjustments that are being made here which move Anthropic's financial results from the red to the black as adjusted often does. The good news is that for adjusted operating income metric there's not actually that much scrubbing being done. Basically, Anthropic is backing out stockbased compensation and non-cash charitable contributions. That's the only difference between its GAP operating losses and its adjusted operating income. But wait a second. Is it fair to back out stockbased compensation? That's for you to decide. But I will say that most major software companies do it. In theory, I don't love backing out stock-based compensation. Why? Because compensation seems like a legitimate expense to me. Should be included. But I'm also a pragmatist. And if I decided to die on that hill, I would have missed out on many great growth stocks over the years. Now, let's talk about the difference between Anthropic's net loss and adjusted net income, which is much more substantial. Specifically, again, using that term gap, the gap numbers, Anthropic reported a net loss of just over $104 billion through the first nine months of 2026, but it's adjusted income showed a profit of $5.6 billion. Now, how is that possible? Well, the key swing factor was a $94 billion line item, an expense described as the change in fair value of convertible notes, derivative liabilities, and safes. That's all cap safes with safe standing for simple agreements for future equity. Without getting too bogged down, I know it's hard not to. Here's what's what this is about. Over the past couple years, Anthropic has reached wide ranging agreements with some partners, you know, part bigname partners, Google, Amazon that include uh many different things. For example, Anthropic gets compute resources from these companies and distribution for its models via their cloud platforms. But in exchange also has committed to spend billions of dollars with those companies. And to this point, Anthropic also issued convertible notes, essentially debt securities that can be converted into anthropic equity as well as other types of securities to Amazon, Google, and other part partners. But as the value of Anthropic has increased substantially, the value of those securities it issued to its partners, well, it's they've grown as well. Each time there's a milestone where Anthropic gets a new higher valuation, it has to account for the increase in the value of those securities at at a cost. Crucially, it's a non-cash cost philanthropic that matters. But while many investors seem happy to dismiss those huge charges because they're non-cash, I'm not sure they should be ignored entirely. And this brings me to my last most important point. There's one element to the anthropic IPO perspectus that's a bit of a mystery, and that's the fact that the company has spent very little of the cash that it's raised. Specifically since its inception, Anthropic has raised approximately $141 billion of capital. But as of the end of September, it had a total of 132 billion in cash cash equivalents and short-term investments on its balance sheet. Okay, how is that possible? Especially since the company's not cash flow positive. It reported its first positive cash flow from operations this year. But even then, it spent much more on investments than it generated from its operating incomes, right? Operating own operating. This is a head scratch. But the answer lies again in those huge deals with the likes of Google and Amazon. Basically, rather than paying cash for its compute, it's given stakes in the company to its partners. So, while you might dismiss those large non-cash chargers as the value of those stacks instead of stakes have grown, I might argue that they are a good approximation of what the company would be paying were it to have paid cash for its infrastructure. But here's the more important point. Anthropic has also disclosed in its IPO perspectus that it has made enormous infrastructure spending commitments for the next several years. I've talked about some of these previously. Remember how I said they'll be paying over $3 billion per month per month to rent SpaceX compute starting next month. That's part of a $120.5 billion deal with SpaceX that runs through 2029. And that's just one of many such infrastructure agreements that Anthropic has made. It has others with Google and Amazon as well as Microsoft and a couple Neoclouds, Nscale, Lambda. Anthropic also has reached agreements directly with with chipmakers like Broadcom, AMD for even more compute. All told, Anthropic says in its IPO perspectus that it is committed to spend approximately $900 billion, substantially all of which is related to comput infrastructure. About half of that will happen by the end of 2030 and about 70 billion is expected to be spent in the next year. Long story short, Anthropic's compute cost, its cash compute cost, they are going to explode. Now, Anthropic published its IPO road show presentation yesterday. And in that deck, they offer what they call a quote long-term financial framework end quote, which shows how they think this will all work out. Basically, they expect to spend 45 to 50% of their revenue on comput and infrastructure, plus another 7 to 10% on revenue a piece on sales and marketing and all other costs, including personnel. It all works out, they say, to a roughly 35% adjusted operating margin in the long run. Well, that's all well and good, but with the numbers for compute commit commitments and the fact that Anthropic expects that spending to amount to less than half of revenue in any given year, you got to assume that this company's going to continually continue growing substantially to the point where it has hundreds of billions of dollars in revenue per per year and soon. That's the only way this work. But it might work. And that really is the bottom line here when it comes to anthropics profitability. Yes, the company has achieved profitability, but only if you strip out some key costs that some would say, including me, shouldn't be stripped out. But the more salient point is that Anthropic is due to spend an enormous amount in the future. So, it needs to continue growing rapidly to outrun those costs and remain profitable. That's the bet you're making if you buy the Anthropic IPO. And just to tell you after all this, I call me intrigued because it is one fast growing company and I care about growth. Bad Money is back after the break. >> Coming up, Kramer's going off the charts to see which restaurant stocks are best positioned to succeed in the current rotation. Next for the past several weeks, as investors have rotated out of tech stocks and the AI trade, many have moved into other groups that have previously been struggling, including many consumer discretionary sectors like the restaurant stocks. When gas prices and interest rates spiked in the back half of the summer, investors left most of the consumer discretionary stocks, as they're called, for dead, fearing that squeeze consumer budgets would result in weak spending uh and make for a tougher operating environment for retailers and restaurants, as it always has. But that assumption turned out to be wrong. We had sequentially positive retail and food services sales growth in both August and September. And it was the food services category doing a lot of the heavy lifting those months. Really kind of extraordinary. Once investors started fleeing tech last month, many restaurant stocks started to rally hard. In just the past few weeks, we've covered several of them, including Chipotle, which you know, we called the bottom one. Uh, Brinker eat, we like that. McDonald's, we saying it's good. Texas royals and Starbucks. Now, the ladder has turned into a big win for my travel trust, which of course you can follow by joining the CBC investing club. To help find some more restaurant stocks that are working in this group, we reached out to Bob Lang, old friend, founder of explosive options.net, net and the author of Know Your Options, who said he sees more upside in three fast food stocks. He likes Wingstop, he likes Shake Shack, and he likes Restaurant Brands International. All three of these companies have delivered strong earnings results in recent weeks. Lang says that they've been able to take price without hurting demand. Highly unusual in this environment. And with relatively low comps from earlier this year, he thinks this could be a sleeper group that's primed to do well into next year as well. But most of all, he likes what he sees from these charts. Okay, we're going to start with one that I haven't been a big fan of at all since it blew up a long time ago. It's called Wing Stop, which uh this one he calls his favorite name in the group. Wing shares have been under pressure for most of the year, but they've had a massive rally, climbing 74% from their late September lows. This is a really nice move. Okay. Uh the the rally has come with good volume trends recently, Lang says, and the stock broke out above some important medium-term resistance levels in mid October. Here at the bottom, which we're looking at, it's the MAC D moving average convergence divergence line. Uh this indicator, which tra tech sign technicians use to measure momentum strength, is now firmly on a buy signal. You can see that really well at the top, the RSI or relative strength index. The wings stop shows a stock is in overbought territory, but Lang says there's no reason to be a seller. Sometimes it's just an incredible show of strength. Okay. Um now he likes that the stock recently retested the 200 day moving average in red and held. That level has gone from resistance to support. Overall, he thinks the recent pattern of higher highs and higher lows for wing shares is a textbook bullish setup. he could see this $167 stock make a run first to $200 and eventually to $250. This would shock me and I don't care for the stock, but I am a huge fan of Bob Lang's work. Next, let's take a look at the chart of Shake Shack, uh, which gapped down after a bad earnings miss in May and has spent most of the past six months in the penalty box, but Lang thinks that the huge gap lower on high volume got some weak hands out of the stock. Look at that. Huh? Uh, and then you got this real long base that Shaq has had just what the bulls need at this point. Many investors are skeptical about buying the stock, but Lang says that makes it a perfect time to be getting long. He noted the stocks break out above the 200 day moving average. Now, the 200 day is in red. Here you've got a right we're starting to really see some This is a fabulous sign uh a powerful move here at the bottom. Lang points out that the MACD recently made a bullish crossover as well. Though he does note that the RSI up here at the top of the chart shows the stock is approaching overbought territory. But he also says that the options flow look good for Shake Shack with a lot of interest in the call options. The one at the 75 and $80 strike expiring later this year and into the first half of 2027. Bob always looks at that stuff. I always thought I respected his work like that. Overall, Lang thinks the gap from May will be filled within the next few weeks. And if he's right, that means about 20 points or maybe 25% upside for Shake Shack, a stock that is expensive. And again, I've been cautious on. I'm growing less cautious when I listen to Bob. The last stock that Lang likes is restaurant brands QSR, parent company of Burger King, Popeye's, Tim Hortons, and the smaller Firehouse Subs. This stock has been rangebound for months with a fairly wide range on moderate volume. Lang says that means the big money is trying to figure out this one. each time it moves into the 80s and you can see this this very interesting pattern. Uh it it it gets knocked back down. Bulls and bears alike are getting frustrated with this stock. Sure they are. Bounce bounce, you know, knockdown, knockdown. Could it happen again? But QSR strong start to this month has caught Lang's attention. The MACD here at the bottom has flipped to a strong buy signal. This is that flip right here. Okay. Uh and the the average start, it's all starting to turn as well. Uh the RSI at the top of the chart shows there's still some room before this one gets too overbought. He likes that. Lang points out that the volume trends here are becoming more bullish as well. You see the volume getting a little bit higher. Overall, Lang wants to watch QSR shares closely as they reapproach the low 80s, a level that has represented resistance a couple times already this year. But if restaurant bears can break out above the key 81 to $82 level, that would be extremely bullish. Lang says a move through that level would confirm a breakout and the stock could easily make it to the triple digits. Here's the bottom line. The charts interpreted by Bob Lang show that the restaurant stocks have made an excellent move higher in recent weeks, but Lang thinks there's still more upside for some of them. He likes Wing Stop best, thinks Shake Shack is looking good, and restaurant brands, well, he's approaching, he says it's approaching a major test as they move back toward pre uh previous highs. Now, if the stock passes that test, then he thinks there's an awful lot of room to run. Chris in Louisiana. Chris. >> Hey, Jim. >> All right. What's happening? >> Can Can we talk stakes? >> Yeah, why not? >> Dart restaurants. Darden restaurants. Jim, should I saddle up or should I saddle out? >> I think that look, I think is absolutely terrific. They offer great value at Olive Garden. I think you should continue to buy the stock. It's even though it's on a spike, I think it does go higher. All right. There's much more mad money ahead, including my exclusive with Tea Pharmaceutical. Then this Veterans Day, I'm shining a light on one fantastic executive whose military service influenced his career and the company itself. And of course, all your calls rapid fire tonight's edition of the lighting round. So stay with Kramer. Recently, Tea Pharmaceutical, one of the world's largest drug makers, released some solid earnings and beat on both the top and bottom lines. and a raise of its fullear sales forecast. Under Richard Francis, who took over in early 2023, Teas put more money behind its own branded drugs in its transformation from a pure play generics company to a biioarma. This was a $9 stock when Francis took the job. It's now above $43. Today, at first ever R&D day, TEFL laid out how its innovative medicines could bring in six to seven billion dollars a year by 2030. Can the next wave of drugs keep this stock running? Let's check in with Richard Francis, Kevin, president, CEO. Mr. Francis, welcome back to Bad Money. >> Thanks. Pleasure to be here. >> I tell you, Rich, I I had to stop myself when I was thinking about this because there would there would have been no reason to have an R&D day before you. >> Yeah. No, it's true. Actually, when I presented today, my first thing I said on the stage was, "This is Tea's first ever R&D day." I remember speaking with previous tea CEOs and they wanted to come on the show and I would always say no because it would always be I felt an embarrassing thing. Well, what have you stolen here? What have you what copyright have you broken there? You are breaking ground in some things that when I saw you in January I actually was critical of because I didn't think you could do it and you have succeeded uh on migraine on tardive disynesia. You're doing some incredible things in schizophrenia. I don't even know where to begin. These are all things I feel that companies won't target. As I mentioned in January, they don't go after because what happens is at their analyst day, they have to say, "I'm sorry, we struck out." What are you doing right that the other guys can't do? >> Well, I think what we actually outlined today in our R&D strategy is we're sort of pragmatic. We go after things where we think there's a high probability of success. We really understand the science deeply and then we think, okay, we can we can make something successful. And a good example of this is well trusa a long acting alanzipene that we launched just a few weeks ago. Now alanzipene as a molecule is regarded as the most efficacious treatment for schizophrenia. The challenge has been no one's been able to make a long acting injectable. Now obviously compliance and adherence for schizophrenia patients who suffer from severe schizophrenia is really important. >> You don't have to be you don't have to do it at the doctor's office. You don't have to monitor it. >> No there's no monitoring required for our world. So what we thought okay how do we crack this long acting? And so we spent a lot of time working on that. But so one could say that we knew the molecule work we just had to make it long acting and once monthly and when we did that and we launched it the reception we've received from the psychiatric community and the patients has been really really positive because that's the unmet medical need. So I think what we do really well is we go after real patients unmet medical need focus where we have real capability whether that's drug delivery or whether that's innovative mechanisms and then we really prosecute it aggressively and we move fast. Well, I I would point out that I have been with another drug company that recently failed on schizophrenia and they told me the reason why is because it's just too hard. There's really no hope. Uh so obviously they should attended your meeting. Maybe they would have found that out. >> It is hard. It is hard. >> Okay. So let's talk about uh bipolar because bipolar is another one that a lot of drug companies have kind of said, well let's just leave it to lamed. Let's leave it to a 1950s anti-seizure drug. Why are you not content with the 1950s anti-seizure drug as a way to be able to treat bipolar? >> Well, I think what we noticed when we launched USAI, our long actit spirit. We now have which is long acting and also been the long acting. So, we really have I think an ability to help 85% of patients who suffer with schizophrenia with well-known molecules. When it came to your study, we expanded that indication into bipolar about 12 to 18 months ago. And obviously, you know, that's the potential we can do with the same with the lands. But what is interesting Jim is we've just uh bought a an asset from a company uh Bio XL which will treat agitation for schizophrenia and bipolar at home. So that's another area where patients really don't have treatment because obviously agitation with bipolar and schizophrenia is very common. Roughly about 2 to three million people have that symptom but they can't be treated at home. So they have to go into hospital into a clinic. So that's just another area where we're treating both schizophrenia and bipolar but building out on our our our schizophrenia franchise to a real scale >> and a joy. How is that different from Norttech or Amovic? >> So uh so AO is a great story. So when we started on the pivot to growth, no one was talking about a job. People thought it had its day. It was $400 million. This year we're going to do over $900 million and we got peak cells of over a billion dollars. The reason why it's doing so well is because >> this is for migraine. I'm sorry. >> This is for migraine. a long acting treatment for migraines. It's a long an injectable CGP and the reason why it's done really well is per firstly it's it's a great product profile. It's very efficacious. It's convenient for the patient. But I think this goes back to our commercial capability at TER as well. We really understand the patient journey whether it's in the United States, whether it's in Europe or other markets. We have grown our market share conceptually. >> Even though it is it is it a copycat CGRP? >> No. No. This is an innovative product we brought to the market many years ago. But I think in our hands what we've shown under the pivot to growth we invested more we understood more and we did the pediatric indication often forgotten. You launch a drug and then you don't do the pediatric. >> Very good point. There is no pediatric for the ones I'm talking about. Finally 2027 what do you have >> 2027 it's going to be a pretty busy year. So obviously we launch well truths at the end of this year. Um we'll have that for the first year. We'll launch eapan a treatment for Tourette's syndrome. So that's a deal we did last year. >> Another one that people say you can't be cured. >> Exactly. I'm super excited about as a father of three just the idea that we can help children in their formative years in a very difficult condition and then obviously we hope to be launching uh uh the the treatment that we got from uh the asset that we bought out of bio XL and and then just keep driving a Jovi waltusa and a treatment for tit disynesia which was up 30% in quarter 3. So we have those and then we have one launch every five years for the next five years and then we have a launch probably every 18 months. >> Well, you should be very proud of what you're doing. I do a lot of work with with the brain because of problems with the brain. I don't mind saying that. People are not supposed to talk about it. That's a that's why brain doesn't get solved because no one talks about it. I do. American Brain Foundation. The stuff you're t tackling is incredible. >> And I I I thank you. >> Well, I thank you for talking about it. Absolutely. Thank you for having us on the show. >> Of course. As Richard Francis, CEO of Tea Pharmaceutical, the old Teva wouldn't I wouldn't put on this tea. I take my money's back for the break. Coming up, he's the fastest mind on Wall Street, so we're putting him to the test with your help. Bring on the lightning round. Next, it is time. It's time for the light. You're playing the sound and then the lightning round is over. Are you ready? Ski daddy. Time for the light round claims. Let's start with Ronald in Florida. Ronald >> Jim Ronald from Wellington, Florida. Alibaba. >> I think Alibaba is the only Chinese stock that I would possibly buy. It's not my favorite right now because the consumer is so weak in China, but it is the only one that I would buy. Let's go because it's got American Financials. Let's go to Roy in New Jersey. Roy, you're happy. >> Hey, Jim. Boy, it's a great pleasure for me to be talking to you. Uh, you're very kind, boy. What's going on? >> The ticker I have is TGB, Triccore Metals, >> speculative copper stock. Speculative copper stock with a lot of copper stock. Still copper still being used in the data center because they haven't converted to fiber yet. I think you can catch a good one. Let's go. But it's back. Robert in Florida. Robert, >> hello. Jim. >> Robert. >> Robert in beautiful Tampa, Florida. Thanks for taking my questions. >> My pleasure. Uh I'm long uh DraftKings at about 25 and as you know they got hammered after the quarter three earnings. Um I'm concerned about their customer acquisition cost and and competition from companies like Kowi. Um I learned though that >> I think you're right. I think you're right to be concerned. There's way too much competition. I don't know. It's it's withering competition. Everybody's a loser and I don't and I think there's too much gambling in the country. That's my own personal view. But it's also been the view began to be the prevailing view at the investment houses of this country. I no longer can possibly recommend any of these gambling stocks because they're all one big >> gamble. Let's go to Bill in Texas. Billy, Jim, >> proud proud club member here and a long time listener. Uh you're still the best. >> A thank you, man. Thank you. Thank you very much. Thank you. How can I help? I want to get your thoughts on one of my favorites, uh, Origin Bank Card, symbol OBK. >> You know, I've got to tell I've actually made a lot of money buying Louisiana banks over the multiple years because there's a lot of consolidation and this is an inexpensive bank stock. Not that good a yield, but I like it. I think you got a good one and I and I actually would encourage you to buy it. Let's go to John in New Jersey. John, >> oh yeah, Jim. >> Oh yeah. >> Um, it's John from Egg Harbor Township. What's your opinion on Palunteer? >> My dad did a lot of business in Egg Harbor. There were like free retail stores that he sold bags to. Um I think that Palanteer stock is worth $200 and Fryer isn't there yet. They did have an excellent quarter. Alex Carp is doing a terrific job. Let's go to Hank in Indiana. Hank. >> Yes. Hello, Mr. Kramer. >> Hey, Hank. What's up? >> Thanks for taking my call. I'll get right to the point. >> All right. >> I'm in my mid70s. My grandson's 10 years old. We both own shares in energy transfer. I bought the shares for potential growth and its dividends. I got two questions for my shares. Should I buy more, hold or sell? For my grandson, should I buy more, hold or sell, and reinvest? >> Okay. For you, I want you to buy more. I think it's sort of for your grandson, it's not risky enough, believe it or not. What you have to do is you have to buy something that has more uh growth to it and and but nothing crazy. I mean, I'm talking about a J&J. I'm talking about a Proctor and Gamble. I would do that because you do not need to worry. You got your He's got his whole life ahead of him. I say don't do that. Buy something more aggressive. Let's go to Spars in California. Spars. Red, white, and blue. 250 years of American exceptionalism. Veterans Day. Booya. Ski. >> Booya is right. And thank you. Thank you everyone for serving. >> All right. >> Doc it. Dr. J, we're looking at Net Scope, NTSK. >> You know, it's just one more cloud security platform. You know, we like Crowd Strike and we like Palo Alto Networks and we don't need any more beyond that. And that, ladies and gentlemen, is the conclusion of the Lightning Round. >> The Lightning Round is sponsored by Charles Schwab. Coming up on this Veterans Day, Kramer is paying tribute to all those who served. Next, tomorrow, kick off the trading day with Squawk on the Street live from Post 9 at the NYSE. >> I am sorry. I I wish I had made it up. You know, would have been better if I had said, David, I have an idea instead of what the truth is, but I'm stuck with the damn truth, which you, by the way, cannot handle. It all starts at 9:00 a.m. Eastern. >> Jim Kramer, the die hard of the dollar. >> Hey, Jimmy. Love the show. >> My 5-year-old grandson loves to watch your show. >> I have to thank you for making us money when it's there to be made. >> Our world is a better place with you in it. We cannot go a whole show without saluting the men and women who serve and have served in our military on this November 11th, known since President Eisenhower as Veterans Day. It's a day where I find myself grasping at the greatness of those who serve, who willing put themselves in harm's way. Like the great Marine colonel I write about at the beginning of How to Make Money in Any Market. A quiet hero who inspired me to start investing after he showed me how he started buying merc as soon as he got back from the war. He built a small fortune. My dad served too in the army. He won a battlefield commission promoted in the midst of a battle when all above his rank were incapacitated or killed in the battle of Lady G of the Philippines. I didn't know what that meant. What? I didn't know what my hero my father was till after he passed away. He was a simple soldier who signed up after Pearl Harbor and served in the Pacific. I didn't know he had done something heroic though until I went to an NFL football game with a man I revered for years and years, Fred Smith, who started FedEx and built it into the colossus that it is today before turning it over to Raj Hubman in 2022. Fred died last year and I wish his passing had gotten more attention given the fabulous career he led and how much he did for veterans while he built FedEx. Fred went to Yale where he studied economics and famously wrote a paper about starting an overnight delivery business which he got either a C or a D on. Fred had forgotten the grade, but he remembered it was a bad one. After graduating, he's then signed up for the Marine Corps to serve in Vietnam. Several times, Fred marveled to me about the old days when you just when you just did that because it was the right thing to do. He did two tours and retired as a captain. He received the Silver Star for gallantry in battle. His citation is too long to list other than to say that he risked his life for his soldiers repeatedly in a battle against the North Vietnamese. In his first tour, he was a grunt. But in his second, he served as a forward air controller, guiding bombing strikes. When I saw him last, he took out a black and white picture of his platoon and told me how many of the men I was looking at were killed in the war. He pointed to each one. It was a somber moment, simply something Fred wanted me to see. He was determined to let me know of these soldiers, to remember them, and I do that this day. Fred took some gambles, literally when FedEx was in its infancy. At one point, after being denied a loan, he took the company's last $5,000, flew to Las Vegas, and turned it into $27,000, playing blackjack, saving the company in the process. He laughed about it when he told me the story. I asked him to tell it to me a couple times. I liked it so much. His service in the military helped guide him through all the years and reversals of his fortune. His successor Raj told me today the FedEx culture was built on people first principles that Smith learned in the military. Our culture is our bedrock. Raj said lots of initial FedEx employees and pilots were from the military and still are from the military. Fred liked the American Battlefield Monuments Foundation which maintains the beautiful cemeteries of Americans who died overseas. He had mentioned my dad in conjunction with that. He said, he told me my dad was a hero. Uh, and that's where I learned of it. I give to the foundation for my travel trust. I do it in honor of Fred. I know Fred will always be known as the person who started the amazingly successful FedEx or the exec who opined most eloquently about the economy at the beginning of a bunch of TV shows I did. But when I spent time with him, he just wanted to talk about the importance of his time in the military and those who served so their deaths and struggles were not in vain. He was quite the man, quite the veteran. Fred, on this day, we salute you and the millions of others who have served along with the men who served with you in Vietnam who never returned. I like to say there's always a bull market somewhere. And I promise try to find it just for you right here on May. I'm Jim Kramer. See you tomorrow. All opinions expressed by Jim Kramer on this podcast are solely Kramer's opinions and do not reflect the opinions of CNBC or its parent company or affiliates and may have been previously disseminated by Kramer on television, radio, internet, or another medium. You should not treat any opinion expressed by Kramer as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Kramer's opinions are based upon information he considers reliable. But neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full MadMoney disclaimer, please visit cnbc.com/madmoney disclaimer.

Commentaires 0

Aucun commentaire pour l'instant. Soyez le premier à partager votre avis !